See more : KeyCorp (0JQR.L) Income Statement Analysis – Financial Results
Complete financial analysis of Acumen Pharmaceuticals, Inc. (ABOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acumen Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Akatsuki Eazima Co., Ltd. (1997.T) Income Statement Analysis – Financial Results
- Norwegian Energy Co ASA (CJ1.SG) Income Statement Analysis – Financial Results
- JIG-SAW INC. (3914.T) Income Statement Analysis – Financial Results
- Maj Invest Danske Aktier (MAJDKA.CO) Income Statement Analysis – Financial Results
- Monument Mining Limited (MMY.V) Income Statement Analysis – Financial Results
Acumen Pharmaceuticals, Inc. (ABOS)
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.44M | 1.70M |
| Cost of Revenue | 42.32M | 169.00K | 4.00K | 8.00K | 8.58K |
| Gross Profit | -42.32M | -169.00K | -4.00K | 1.43M | 1.69M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.44% | 99.49% |
| Research & Development | 42.32M | 32.36M | 12.31M | 8.00M | 8.58M |
| General & Administrative | 18.82M | 12.88M | 7.28M | 1.35M | 926.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.82M | 12.88M | 7.28M | 1.35M | 926.00K |
| Other Expenses | 0.00 | -11.00K | 51.00K | 0.00 | 0.00 |
| Operating Expenses | 61.14M | 45.24M | 19.58M | 9.35M | 9.50M |
| Cost & Expenses | 61.14M | 45.24M | 19.58M | 9.35M | 9.50M |
| Interest Income | 10.21M | 2.39M | 84.00K | 1.00K | 45.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 184.00K | 169.00K | 4.00K | 7.91M | 7.81M |
| EBITDA | -51.61M | -42.69M | 61.58M | 587.00K | 119.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -591.78% | -451.27% |
| Operating Income | -61.14M | -45.24M | 61.57M | -7.91M | -7.81M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -550.97% | -459.93% |
| Total Other Income/Expenses | 8.77M | 2.38M | -81.02M | 587.00K | -102.00K |
| Income Before Tax | -52.37M | -42.86M | -100.61M | -7.33M | -7.91M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -510.10% | -465.94% |
| Income Tax Expense | 0.00 | -2.38M | 81.07M | -1.00K | -45.00K |
| Net Income | -52.37M | -40.48M | -181.68M | -7.32M | -7.86M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -510.03% | -463.29% |
| EPS | -1.08 | -1.00 | -4.49 | -0.18 | -0.20 |
| EPS Diluted | -1.08 | -1.00 | -4.49 | -0.18 | -0.20 |
| Weighted Avg Shares Out | 48.49M | 40.60M | 40.47M | 40.15M | 40.15M |
| Weighted Avg Shares Out (Dil) | 48.61M | 40.60M | 40.47M | 40.15M | 40.15M |
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
NEWTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced...
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Acumen Pharmaceuticals develops treatments for Alzheimer's disease targeting toxic AβOs, with promising results for sabirnetug in phase 1 clinical trial Intercept-AD. The potential for early AD is approximately 7 million patients, positioning ABOS for significant market share if successful. Sabirnetug's...
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease
NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) in the brain for the treatment of Alzheimer's disease (AD), today announced that...
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new findings from...
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Alex Braun - Vice President & Head of Investor Relations Daniel O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer...
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
CHARLOTTESVILLE, Va., May 14, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today...
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate...
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate...
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first...
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced...
Source: https://incomestatements.info
Category: Stock Reports